Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pfizer Inc"


25 mentions found


(Reuters) - Wall Street’s main indexes were set to open higher on Tuesday as better-than-expected factory data from China and hopes that a COVID-19 vaccine will be rolled out before the end of the year bolstered bets of a speedy economic recovery. FILE PHOTO: A Wall St. sign is seen near the New York Stock Exchange (NYSE) in the financial district in New York, U.S., November 24, 2020. REUTERS/Brendan McDermid/File PhotoInvestors are closely following updates on a handful of leading vaccine candidates as well as the start of global shipments as drugmakers submit paperwork for regulatory approvals. ET, Dow E-minis were up 299 points, or 1.01% and S&P 500 E-minis were up 0.93%. Tesla Inc rose about 4.5% after S&P Dow Jones Indices said it would add one of Wall Street’s most valuable companies to the S&P 500 index all at once on Dec. 21.
Persons: Brendan McDermid, , Steven Blitz, Dow, Steven Mnuchin, Jerome Powell, Powell Organizations: Reuters, New York Stock Exchange, REUTERS, Pfizer Inc, Moderna, TS Lombard, Investors, Carnival Corp, Royal Caribbean Cruises Ltd, Delta Air Lines Inc, United Airlines Holdings, Big, Dow E, Nasdaq, Federal, Communications, Tesla, Dow Jones Indices Locations: China, New York, U.S, EU, United States, California, Big U.S
WASHINGTON (Reuters) - The United States entered the final month of the year hoping that promising vaccine candidates will soon be approved to halt the rapidly spreading novel coronavirus after 4.2 million new cases were reported in November. FILE PHOTO: A health worker provides a COVID-19 test at a drive-through testing site, as the coronavirus disease (COVID-19) continues to spread, in Staten Island, New York, U.S. November 25, 2020. “One hundred percent of the Americans that want the vaccine will have the vaccine by (June). We will have over 300 million doses available to the American public well before then,” Paul Ostrowski, the vaccine program’s director of supply, production and distribution, told MSNBC television on Monday. “If these trends continue, we’re going to have to take much more dramatic, arguably drastic, action.”
Persons: Brendan McDermid, Donald Trump’s, Johnson, ” Paul Ostrowski, Webster, Trump, Joe Biden, Biden, California’s, Gavin Newsom Organizations: WASHINGTON, United, REUTERS, U.S . Food, Drug Administration, Pfizer Inc, Moderna Inc, AstraZeneca PLC, Johnson, Trump, MSNBC, Reuters, Merriam Locations: United States, Staten Island , New York, U.S,
Pfizer-BioNTech apply for EU emergency authorization for COVID-19 vaccine
  + stars: | 2020-12-01 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a Pfizer logo in this illustration taken November 29, 2020. REUTERS/Dado Ruvic/IlustrationFRANKFURT (Reuters) - Pfizer Inc and BioNTech have applied to the European drugs regulator for conditional authorization of their COVID-19 vaccine, following similar steps in the United States and Britain, the companies said on Tuesday. The application to the European Medicines Agency (EMA) comes after the companies applied for U.S. approval on Nov. 20, taking them a step closer to launching their vaccine. The European filing completes the so-called rolling review process, which was initiated with the EMA on Oct. 6. The British government said here last week that the U.S.-German partners had reported the data from their clinical trials to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Persons: Dado Ruvic, Germany’s BioNTech Organizations: Pfizer, REUTERS, Pfizer Inc, European Medicines Agency, Moderna, EMA, UK Medicines, Healthcare, Agency Locations: FRANKFURT, United States, Britain, EU, COVID, U.S
FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a Pfizer logo in this illustration taken November 29, 2020. REUTERS/Dado Ruvic/IlustrationFRANKFURT (Reuters) - Pfizer Inc and BioNTech’s COVID-19 vaccine could be rolled out in Europe this month, the companies said on Tuesday after they applied for EU emergency approval for the shot. The application to the European Medicines Agency (EMA) comes days after the companies applied for emergency use of their vaccine in the United States. In their pursuit of a European launch, the partners are neck-and-neck with rival Moderna, which said on Monday it would ask the EU regulator to recommend conditional approval for its shot. The European filing completes the so-called rolling review process, which was initiated with the EMA on Oct. 6.
Persons: Dado Ruvic, BioNTech’s, , Germany’s BioNTech, BioNTech Organizations: Pfizer, REUTERS, Pfizer Inc, European Medicines Agency, COVID, CMA, Moderna, EU, United, EMA, Medicines, Healthcare, Agency Locations: FRANKFURT, Europe, United States, European Union, EU, COVID
The European Medicines Agency said its officials will work through Christmas to review whether data from trials show sufficient proof of the two vaccines’ safety and effectiveness. If so, the vaccines could be marketed as soon as this month, according to people familiar with the discussions. The EMA is set to make a judgment on the BioNTech vaccine first, by Dec. 29 at the latest, giving that candidate a two-week edge in the vaccine race over Moderna’s candidate. The agency will then decide whether to authorize the Moderna vaccine by Jan. 12, officials said. The submission marked a milestone in the race to supply the world with a working vaccine to end the pandemic, said Ugur Sahin, the chief executive of BioNTech.
Persons: BioNTech, Jan, Ugur Sahin, , ” Dr, Sahin Organizations: BERLIN, Pfizer Inc, drugmaker Moderna Inc, European Union, European Medicines Agency Locations: Italy, Belgium, France
Pfizer, BioNTech File for Covid-19 Vaccine Approval in Europe
  + stars: | 2020-12-01 | by ( Bojan Pancevski | Drew Hinshaw | ) www.wsj.com sentiment -0.99   time to read: 1 min
BERLIN—Pfizer Inc. and partner BioNTech SE said they are seeking approval from the European Union for their coronavirus vaccine. The companies, which have already applied for authorization in the U.S. and U.K., submitted an application on Monday to the European Medicines Agency. That application was accepted on Tuesday by the regulator, the companies said.
Persons: BioNTech Organizations: BERLIN, Pfizer Inc, European Union, European Medicines Agency Locations: U.S
A vaccine from Moderna Inc could follow a week later, he said, after the company announced on Monday that it would apply for U.S. and European emergency authorization. “So we could be seeing both of these vaccines out and getting into people’s arms before Christmas,” Azar said on CBS’ “This Morning.”The federal government will ship the vaccines. The United States has reported more than 4 million new COVID-19 cases so far in November and more than 35,000 coronavirus-related deaths, according to a Reuters tally. That number is still about 60% lower than the comparable day last year when 2.88 million passengers were screened, the highest ever recorded by the agency. De Blasio said schools would begin to reopen for in-person learning on Dec. 7, starting with elementary schools for students whose parents agree to a weekly testing regimen for the novel coronavirus.
Persons: Alex Azar, Erin Scott, Pfizer Inc’s, ” Azar, , Mike Pence, Dr, Anthony Fauci, ABC’s, Bill de Blasio, De Blasio, “ We’ve, ” de Blasio Organizations: WASHINGTON, . Health, Human Services, White, REUTERS, Health, Pfizer Inc’s COVID, Food and Drug Administration, Moderna Inc, U.S, CBS, United, Reuters, Transportation Security Administration, CNN Locations: U.S, Brady, Washington , U.S, United States, New York City,
Final trial data showed the vaccine to be 94.1% effective at preventing COVID-19, comparable with Pfizer’s results. “So we could be seeing both of these vaccines out and getting into people’s arms before Christmas,” Azar said on CBS’ “This Morning.”The federal government will ship the vaccines. The United States has reported 4.2 million new COVID-19 cases so far in November and more than 36,000 coronavirus-related deaths, according to a Reuters tally. Health officials found the rate of people testing positive in public schools to be significantly lower than in the city and state. “The schools are some of the safest places to be right now in New York City,” de Blasio told CNN.
Persons: Alex Azar, Erin Scott, Pfizer Inc’s, ” Azar, Dr, Anthony Fauci, ABC’s, , Andrew Cuomo, Phil Murphy, Murphy, Bill de Blasio, ” de Blasio Organizations: WASHINGTON, . Health, Human Services, White, REUTERS, Health, Pfizer Inc’s COVID, Food and Drug Administration, Moderna Inc, U.S, CBS, United, Reuters, Transportation Security Administration, , ” New, Twitter, CNN Locations: U.S, Brady, Washington , U.S, COVID, United States, ” New York, New Jersey, New York City,
Final trial data showed the vaccine to be 94.1% effective at preventing COVID-19, comparable with Pfizer’s results. “So we could be seeing both of these vaccines out and getting into people’s arms before Christmas,” Azar said on CBS’ “This Morning.”The federal government will ship the vaccines. The United States has reported 4.2 million new COVID-19 cases so far in November and more than 36,000 coronavirus-related deaths, according to a Reuters tally. Murphy, who has brought back a series of COVID-19 restrictions in recent weeks, also said all indoor youth and adult sports will be put on hold from Dec. 5 through Jan. 2, 2021, also with exemptions. But many appear to have disregarded those pleas as the Transportation Security Administration screened 1.18 million airline passengers on Sunday, the highest since mid-March.
Persons: Alex Azar, Erin Scott, Pfizer Inc’s, ” Azar, Gavin Newsom, , Andrew Cuomo, Phil Murphy, Murphy, Dr, Anthony Fauci, ABC’s Organizations: ANGELES, Reuters, . Health, Human Services, White, REUTERS, Health, Pfizer Inc’s COVID, Food and Drug Administration, Moderna Inc, U.S, CBS, United, , ” New, Twitter, Transportation Security Administration Locations: WASHINGTON, U.S, Brady, Washington , U.S, COVID, United States, California, ” New York, New Jersey
LOS ANGELES (Reuters) - California’s governor said on Monday the state was at a “tipping point” in the COVID-19 pandemic that would soon overwhelm hospitals as political leaders nationwide turn to increasingly aggressive measures to hold back the latest surge. “(California) has worked hard to prepare for a surge - but we can’t sustain the record high cases we’re seeing,” Newsom said on Twitter. “Current projections show CA will run out of current ICU beds before Christmas Eve. The governor told reporters discussions were underway among state health officials over the potential stay-at-home order. More than 4.2 million new COVID-19 infections and 36,000 COVID-19 related deaths were reported across the United States in November, according to a Reuters tally.
Persons: Gavin Newsom, ” Newsom, Newsom, Alex Azar, Azar, ” Azar, Andrew Cuomo, ” Cuomo, Phil Murphy, Murphy Organizations: ANGELES, Reuters, Twitter, Pfizer Inc, Moderna, Health, Food and Drug Administration, CBS, , . New Locations: California’s, California, Napa, United States, U.S, Europe, Los Angeles, New York, ., . New Jersey
While smaller names typically see outsized price moments compared to their larger brethren, the small cap gains for November have nearly doubled the roughly 11% gain in the S&P 500 this month. Small cap stocks are generally seen as the first to recover as the U.S. economy pulls out of a recession. In the large cap S&P 500, the same four sectors account for about 24.5% of the overall index weighting. Graphic: 20-year performance of Russell to S&P 500In addition, small caps appear comparatively cheap, even with the strong November performance. Graphic: Small cap price to earnings relative to large capWhile the longer economic outlook may be positive, the next few months are expected to be rocky, which could lead to some volatility for small caps.
Persons: Brendan McDermid, Russell, , Tom Hainlin, “ You’ve, Steven DeSanctis, DeSanctis, Keith Lerner, Michael Feroli, It’s, Morgan, Lisa Shalett, Sam Stovall, Stovall Organizations: YORK, REUTERS, Netflix Inc, Moderna Inc, Pfizer Inc, U.S, Bank, Group, Jefferies, FTSE Russell, Suntrust, Services, JPMorgan, Federal, Morgan Stanley Wealth Management, Research Locations: U.S, Wall St, New York, COVID, Minneapolis, Atlanta
Two coronavirus vaccines available in U.S. in coming weeks: health secretary
  + stars: | 2020-11-30 | by ( Reuters Staff | ) www.reuters.com sentiment -0.96   time to read: +1 min
FILE PHOTO: U.S. Secretary of Health and Human Services Alex Azar testifies to the House Select Subcommittee on the coronavirus disease (COVID-19) crisis, on Capitol Hill in Washington, U.S., October 2, 2020. Michael A. McCoy/Pool via REUTERSWASHINGTON (Reuters) - The first two vaccines against the novel coronavirus could be available to Americans before Christmas, Health Secretary Alex Azar said on Monday, after Moderna Inc became the second vaccine maker likely to receive U.S. emergency authorization. The Food and Drug Administration’s outside advisers will meet on Dec. 10 to consider authorizing Pfizer Inc’s COVID-19 vaccine. That vaccine could be approved and shipped within days, with Moderna’s following one week behind that, Azar said. “They will be determining which groups to be prioritized.
Persons: Alex Azar, Michael A, Pfizer Inc’s, Azar, ” Azar, , Mike Pence Organizations: Health, Human, Capitol, McCoy, REUTERS WASHINGTON, Christmas, Moderna Inc, Pfizer, Pfizer Inc’s COVID, CBS Locations: Washington , U.S
Factbox: Moderna's mRNA coronavirus vaccine
  + stars: | 2020-11-30 | by ( Reuters Staff | ) www.reuters.com + 0.00   time to read: +4 min
Pfizer’s vaccine also uses mRNA technology. - Other firms developing COVID-19 vaccines that use mRNA technology include Germany’s Curevac and U.S. biotech firm Arcturus Therapeutics Holdings Inc.- An authorized, safe and effective mRNA vaccine for COVID-19 would be a first for the technology, which has previously not been used for an approved vaccine or drug. - Moderna’s vaccine can be stored for up to six months at -20 Celsius though it is expected to be stable for 30 days at normal fridge temperatures of 2 to 8 degrees Celsius (36°-46°F). REGULATORY AND PRODUCTION TIMELINE- The United Kingdom’s health regulator started a real-time review of its experimental COVID-19 vaccine in October. TRIALS- The company was among the first to conduct COVID-19 vaccine human trials, starting in March and its late-stage 30,000 participant testing began on July 27 in the United States.
Persons: Dado Ruvic, Moderna, Takeda Israel Organizations: Reuters, Moderna Inc, COVID, REUTERS, U.S . Food, Drug Administration, European Union, Pfizer Inc, BioNTech, Moderna, U.S, Arcturus Therapeutics Holdings Inc, European Medicines Agency, Biomedical Advanced Research, Development Authority, National Institute of Allergy, National Institutes of Health Locations: U.S, Canada, Switzerland, United States, MODERNA, Japan, Qatar
(Reuters) - Moderna Inc said on Monday it has applied for U.S. emergency authorization for its COVID-19 vaccine after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns. Moderna reported 30 severe cases, all in the placebo group. Switzerland’s Lonza Group , which has a contract with Moderna to supply ingredients for the vaccine, rose 4.4%. Both the Moderna and Pfizer vaccines proved more effective than anticipated and far superior to the 50% approvable benchmark set by FDA. Moderna reported no new side effects since its interim analysis, the most common of which were fatigue, injection site redness and pain, headache and body aches, which rose after the second dose and were short-lived.
Persons: Tal Zaks, , COVID, , Alexander Edwards, Moderna, Gillies, , Switzerland’s, Dado Ruvic, it’s, Zaks, you’ve, Moderna’s Organizations: Reuters, Moderna Inc, U.S . Food, Drug Administration, Pfizer Inc, FDA, Moderna, ” Moderna, , Britain’s University of Reading, European Medicines Agency, Britain’s Faculty of Pharmaceutical Medicine, Medicines, Healthcare, Agency, Switzerland’s Lonza, Pfizer, AstraZeneca, REUTERS, McKesson Corp Locations: U.S, United States
Moderna Asks Health Regulators to Authorize Its Covid-19 Vaccine
  + stars: | 2020-11-30 | by ( Peter Loftus | ) www.wsj.com sentiment -0.98   time to read: +1 min
Moderna Inc. said it asked U.S. and European health regulators Monday to authorize use of its Covid-19 vaccine, after it was shown to be 94.1% effective in a full analysis of a pivotal study. In the 30,000-person trial, 196 subjects developed Covid-19 with symptoms after receiving either the vaccine or a placebo, Moderna said. Of those, 185 had taken a placebo, while only 11 had gotten the vaccine, indicating it protects against the disease. Moderna also said the vaccine appeared to be generally safe, though some subjects developed headaches and other mild to moderate reactions. “I think this vaccine is going to be really a game changer for this pandemic,” Moderna Chief Executive Stéphane Bancel said in an interview.
Persons: Moderna, Stéphane Bancel, , Organizations: Inc, U.S, Pfizer Inc, ” Moderna Locations: U.S, Europe
UK business confidence at four-month low but signs of vaccine boost: Lloyds
  + stars: | 2020-11-30 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
FILE PHOTO: People walk during the morning rush hour in the financial district of Canary Wharf amid the outbreak of the coronavirus disease (COVID-19) in London, Britain September 28, 2020. Lloyds Bank’s business barometer sank by 3 points to -21 for the month as a whole, hit by nervousness about Britain’s chances of a post-Brexit trade deal as well as the pandemic measures. But responses in the second week of the survey saw confidence rise by three points to -15, coinciding with the Nov. 9 announcement by Pfizer Inc about the effectiveness of a coronavirus vaccine developed with German partner BioNTech. Lloyds’ survey of 1,200 firms was conducted between Nov. 2 and 16, covering the start of a month-long lockdown for England. A third of firms planned a pay freeze, up from 14% at the start of 2020, Lloyds said.
Persons: Toby Melville LONDON, BioNTech Organizations: REUTERS, Lloyds, Pfizer Inc Locations: Canary, London, Britain, England
Moderna to Ask Health Regulators to Authorize Its Covid-19 Vaccine
  + stars: | 2020-11-30 | by ( Peter Loftus | ) www.wsj.com + 0.55   time to read: 1 min
Moderna Inc. said it will on Monday ask U.S. and European health regulators to authorize use of the company’s Covid-19 vaccine, after it was shown to be 94.1% effective in a full analysis of a pivotal study. The timing keeps the vaccine on track to become possibly the second to go into use in the U.S. by year’s end—after one already under regulatory review from Pfizer Inc. and BioNTech SE—with inoculation available to the general public likely in spring or summer.
Organizations: Inc, Pfizer Inc Locations: U.S
UK secures 2 million more doses of Moderna's COVID-19 vaccine
  + stars: | 2020-11-29 | by ( Reuters Staff | ) www.reuters.com sentiment -0.95   time to read: +2 min
REUTERS/Dado Ruvic/Illustration/File Photo(Reuters) - Britain has secured two million doses of Moderna Inc’s COVID-19 vaccine candidate, to be available in Europe as early as the spring, the government said on Sunday, in addition to the 5 million doses it secured from the U.S. company two weeks ago. Britain now has access to enough doses of Moderna’s vaccine candidate for around 3.5 million people. Overall, it has access to 357 million doses of vaccines from seven developers, according to government statement. Moderna’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial. Britain has also secured 100 million doses of the vaccine developed by AstraZeneca PLC and Oxford University and has targeted a rollout to begin before Christmas.
Persons: Dado Ruvic, Boris Johnson, Nadhim, Matt Hancock Organizations: REUTERS, Moderna, U.S ., Medicines, Healthcare, Agency, Germany’s, Pfizer Inc, Pfizer, Financial Times, AstraZeneca PLC, Oxford University Locations: Britain, Europe, U.S, COVID, United States
UK secures 2 million more doses of Moderna's Covid vaccine
  + stars: | 2020-11-29 | by ( ) www.cnbc.com sentiment -0.93   time to read: +2 min
Britain has secured two million doses of Moderna Inc's Covid-19 vaccine candidate, to be available in Europe as early as the spring, the government said on Sunday, in addition to the 5 million doses it secured from the U.S. company two weeks ago. Britain now has access to enough doses of Moderna's vaccine candidate for around 3.5 million people. Overall, it has access to 357 million doses of vaccines from seven developers, according to government statement. Moderna's experimental vaccine is 94.5% effective in preventing Covid-19 based on interim data from a late-stage trial. Britain has also secured 100 million doses of the vaccine developed by AstraZeneca PLC and Oxford University and has targeted a rollout to begin before Christmas.
Persons: Boris Johnson, Nadhim, Matt Hancock Organizations: Moderna Inc, Moderna, U.S ., Medicines, Healthcare, Agency, Germany's, Pfizer Inc, Pfizer, Financial Times, AstraZeneca PLC, Oxford University Locations: COVID, Britain, Europe, U.S, Covid, United States
UK regulator set to approve COVID-19 vaccine next week - FT
  + stars: | 2020-11-28 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
REUTERS/Dado Ruvic/File Photo(Reuters) - Britain is set to approve the COVID-19 vaccine developed by BioNTech SE and Pfizer Inc next week and deliveries would begin within hours of the authorisation, the Financial Times reported on Saturday. The first immunisations using the BioNTech and Pfizer vaccine could take place from Dec. 7, the FT said, citing unnamed sources. Britain said on Nov. 20 it had formally asked its medical regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), to assess the Pfizer-BioNTech COVID-19 vaccine for its suitability, the first step in making it available outside the United States. The government asked the regulator on Friday to assess AstraZeneca Plc’s COVID-19 vaccine for a possible rollout. It has secured 100 million doses of the vaccine developed by AstraZeneca and Oxford University and has targeted a rollout to begin before Christmas.
Persons: Dado, Boris Johnson, Nadhim Zahawi Organizations: Pfizer, REUTERS, BioNTech, Pfizer Inc, Financial Times, British, Medicines and Healthcare Products Regulatory Agency, AstraZeneca Plc’s COVID, AstraZeneca, Oxford University Locations: Britain, United States
A green light for any vaccine would come as welcome news to Americans, who political leaders have clamped under increasingly aggressive measures to curtail the spread of the virus. But the ruling could drive legal challenges against similar limits placed on houses of worship in other states, including California. “Remember, skip the crowds and shop from home this Black Friday,” Kentucky Governor Andy Beshear, a first-term Democrat, wrote on Twitter. Some politicians and health experts feared Americans traveling for Thanksgiving could spread the contagion. Many heeded advice to stay home on Thursday but others chose to travel, saying they were willing to risk illness to see family.
Persons: Lucy Nicholson, Andrew Cuomo, ” Randy Mastro, Muriel Bowser, lockdowns, Andy Beshear, Michelle Lujan Grisham, Grisham Organizations: D.C, Los, Los Angeles Mission, REUTERS, U.S . Centers for Disease Control, Prevention, and Drug Administration, United Airlines, Pfizer Inc, CDC, Supreme, Catholic Archdiocese of, Reuters, Washington D.C, , Twitter, New, Democrat, Transportation Security Administration Locations: Los Angeles, Los Angeles , California, U.S, Angeles County, New York, California, Catholic Archdiocese of Brooklyn, ” Kentucky, New Mexico, Curry County, United States
NEW YORK (Reuters) - Pandemic-weary Americans entered the holiday season on Friday under strong pressure from political leaders and health officials to stay home, avoid most gatherings and curtail Christmas shopping as the coronavirus surged nationwide. REUTERS/Lucy NicholsonOne day after the nation celebrated a muted Thanksgiving, malls and retailers imposing strict COVID-19 rules saw fewer Americans in stores for the traditional Black Friday start of the holiday shopping season. Some politicians and health experts have said that Americans traveling for the Thanksgiving holiday could spread the contagion even faster and push the already strained healthcare system to the brink. Many Americans heeded the advice to stay home for Thanksgiving on Thursday. Nearly 6 million Americans traveled by air from Friday to Wednesday, it said, a number that is however less than half that of the same period last year.
Persons: Lucy Nicholson, Andy Beshear, CUOMO, Andrew Cuomo, Cuomo, ” Randy Mastro, Muriel Bowser, Michelle Lujan Grisham, Grisham Organizations: YORK, Los, Los Angeles Mission, REUTERS, , Twitter, Pfizer Inc, Moderna, U.S . Centers for Disease Control, SUPREME, U.S, Supreme, New York, Catholic Archdiocese of, Reuters, New, Democrat, Transportation Security Administration Locations: Los Angeles, Los Angeles , California, U.S, ” Kentucky, COVID, New, Catholic Archdiocese of Brooklyn, Washington ,, New Mexico, Curry County, United States
Wall Street rises, Nasdaq hits record high on recovery hopes
  + stars: | 2020-11-27 | by ( Shivani Kumaresan | ) www.reuters.com + 0.00   time to read: +3 min
FILE PHOTO: The front facade of the New York Stock Exchange (NYSE) is seen in New York, U.S., November 24, 2020. Nine of the 11 major S&P sectors were higher, with only the real estate and the utilities sectors, commonly considered defensive, trading lower. Market volatility, as measured by the CBOE volatility index, slipped to pre-pandemic levels. Trading volumes are expected to be light as the U.S. stock market closes early on Friday. The S&P index recorded 17 new 52-week highs and no new low, while the Nasdaq recorded 75 new highs and four new lows.
Persons: Brendan McDermid, Donald Trump, Joe Biden, , Rick Meckler, Meckler Organizations: Reuters, Nasdaq, New York Stock Exchange, REUTERS, Electoral, Cherry Lane Investments, Pfizer Inc, Moderna Inc, Dow Jones, Dow, iQIYI Inc, Alibaba, Holding, Tencent Holdings, NYSE Locations: New York, U.S, New Jersey
Nasdaq hits record high as holiday shopping begins
  + stars: | 2020-11-27 | by ( Stephen Culp | ) www.reuters.com + 0.00   time to read: +3 min
NEW YORK (Reuters) - Wall Street stocks advanced and the Nasdaq closed at a record high on Friday in a holiday-shortened week, as retailers kicked off the year-end shopping season amid record COVID-19 hospitalizations. FILE PHOTO: The front facade of the New York Stock Exchange (NYSE) is seen in New York, U.S., November 24, 2020. REUTERS/Brendan McDermid/File PhotoThe Nasdaq outperformed as investors favored tech-related, market-leading stocks that have fared well during the pandemic, while economically sensitive cyclical stocks weighed. “Black Friday has been somewhat tarnished - traffic is down due to the pandemic - but the good news is e-commerce sales have reached a new record,” Cardillo said. Chipmaker stocks, which have been resilient throughout the global health crisis, once again outperformed the broader market.
Persons: Brendan McDermid, Dow, , Peter Cardillo, bode, ” Cardillo, , Jobs Organizations: YORK, Nasdaq, New York Stock Exchange, REUTERS, Spartan Capital Securities, ” Retailers, , COVID, AstraZeneca, U.S, Pfizer Inc, Moderna Inc, Dow Jones, Walt Disney, Tesla, iQIYI Inc, Reuters, Alibaba, Holding, Tencent Holdings Locations: New York, U.S
Wall St. gains, Nasdaq hits record high as holiday shopping begins
  + stars: | 2020-11-27 | by ( Stephen Culp | ) www.reuters.com + 0.00   time to read: +3 min
NEW YORK (Reuters) - Wall Street stocks advanced, with the Nasdaq closing at a record high, on Friday in a holiday-shortened week as retailers kicked off the year-end shopping season amid record COVID-19 hospitalizations. The Nasdaq outperformed as investors favored tech-related, market-leading stocks that have fared well during the pandemic, while economically sensitive cyclical stocks weighed. All three indexes rose for the week, in which the S&P 500 reached a new closing high and the blue-chip Dow ended above 30,000 for the first time ever. Of the 11 major sectors in the S&P 500, healthcare companies enjoyed the largest percentage gains while energy shares had the biggest percentage loss. The S&P 500 posted 23 new 52-week highs and no new lows; the Nasdaq Composite recorded 154 new highs and nine new lows.
Persons: Dow, , Peter Cardillo, bode, ” Cardillo, , Brendan McDermid, Jobs, decliners Organizations: YORK, Nasdaq, Spartan Capital Securities, ” Retailers, New York Stock Exchange, REUTERS, COVID, AstraZeneca, U.S, Pfizer Inc, Moderna Inc, Dow Jones, Philadelphia, Walt Disney Co, Tesla, iQIYI Inc, Reuters, Alibaba, Holding, Tencent Holdings, NYSE Locations: New York, U.S
Total: 25